{"altmetric_id":5098679,"counts":{"readers":{"mendeley":1,"citeulike":0,"connotea":0},"total":{"posts_count":6},"news":{"unique_users_count":2,"unique_users":["medcity_news","seeking_alpha"],"posts_count":6}},"citation":{"altmetric_jid":"4f6fa6063cf058f6100067c0","authors":["Lara P. Stepan","Esther S. Trueblood","Kari Hale","John Babcook","Luis Borges","Claire L. Sutherland"],"doi":"10.1369\/0022155411410430","endpage":"710","first_seen_on":"2016-02-05T16:04:39+00:00","issns":["0022-1554","1551-5044"],"issue":"7","journal":"Journal of Histochemistry and Cytochemistry","last_mentioned_on":1494268599,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3201164\/","https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3201164\/"],"pmid":"21551320","pubdate":"2011-07-01T00:00:00+00:00","publisher":"Histochemical Society","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"701","subjects":["histocytochemistry"],"title":"Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues: Potential Implications as a Cancer Therapeutic Target","type":"article","uri":"http:\/\/journals.sagepub.com\/doi\/10.1369\/0022155411410430","volume":"59","mendeley_url":"http:\/\/www.mendeley.com\/research\/expression-trop2-cell-surface-glycoprotein-normal-tumor-tissues"},"altmetric_score":{"score":14,"score_history":{"1y":14,"6m":14,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":14},"context_for_score":{"all":{"total_number_of_other_articles":8172683,"mean":6.9158600214652,"rank":589133,"this_scored_higher_than_pct":92,"this_scored_higher_than":7576251,"rank_type":"exact","sample_size":8172683,"percentile":92},"similar_age_3m":{"total_number_of_other_articles":332603,"mean":9.6947570249122,"rank":31954,"this_scored_higher_than_pct":90,"this_scored_higher_than":300309,"rank_type":"exact","sample_size":332603,"percentile":90},"this_journal":{"total_number_of_other_articles":509,"mean":2.9092913385827,"rank":4,"this_scored_higher_than_pct":99,"this_scored_higher_than":505,"rank_type":"exact","sample_size":509,"percentile":99},"similar_age_this_journal_3m":{"total_number_of_other_articles":13,"mean":2.2903333333333,"rank":1,"this_scored_higher_than_pct":92,"this_scored_higher_than":12,"rank_type":"exact","sample_size":13,"percentile":92}}},"demographics":{"users":{"mendeley":{"by_status":{"Student  > Ph. D. Student":1},"by_discipline":{"Biochemistry, Genetics and Molecular Biology":1}}}},"posts":{"news":[{"title":"Seattle Genetics signs $2B deal for solid tumor ADC","url":"http:\/\/ct.moreover.com\/?a=29542868634&p=1pl&v=1&x=GKfk-Ytcm6Ay7ccT8Oabpw","license":"public","citation_ids":[5098679],"posted_on":"2017-02-10T21:01:46+00:00","summary":"Seattle Genetics has secured global rights to Immunomedics\u2019 antibody-drug conjugate IMMU-132 (sacituzumab govitecan), currently in late-stage trials for triple-negative metastatic breast cancer.","author":{"name":"Medcity News","url":"http:\/\/medcitynews.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/957\/normal\/Screen_Shot_2016-02-02_at_16.37.55.png?1454431086"}},{"title":"Seattle Turns To Buying In Growth","url":"http:\/\/ct.moreover.com\/?a=29583585589&p=1pl&v=1&x=YaCK2tZjBYe5yi7cBUD3Xw","license":"public","citation_ids":[5098679],"posted_on":"2017-02-14T14:30:02+00:00","summary":"Seattle Genetics (NASDAQ: SGEN ), facing slowing growth for its big earner Adcetris and a wait before new indications bolster sales, has looked elsewhere for expansion.","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}},{"title":"Immunomedics up 32% on improved prospects for IMMU-132","url":"http:\/\/ct.moreover.com\/?a=25362240522&p=1pl&v=1&x=ESmuAuBaTAsdyWx_xAjQ7w","license":"public","citation_ids":[5098679],"posted_on":"2016-02-05T15:52:52+00:00","summary":"Micro cap Immunomedics ( IMMU +32.4%) jumps out of the blocks this morning on a 6x surge in volume in apparent response to the news that the FDA has designated Fast Track-tagged IMMU-132 a Breakthrough Therapy for the treatment of triple negative\u2026","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}},{"title":"New data on Immunomedics' lead ADC candidate IMMU-132 still positive; U.S. marketing application on tap for mid-year; shares ahead 3%","url":"http:\/\/ct.moreover.com\/?a=29276101723&p=1pl&v=1&x=Al94_F8n2FbJz9Bn3bftSg","license":"public","citation_ids":[5098679],"posted_on":"2017-01-18T17:50:39+00:00","summary":"Immunomedics ( IMMU +3.2%) perks up average volume in response to its announcement of new data related to lead antibody-drug conjugate (ADC) candidate IMMU-132 (sacituzumab govitecan) in triple negative breast cancer (TNBC).","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}},{"title":"Immunomedics up 28% premarket on license deal with Seattle Genetics for lead product candidate IMMU-132 valued as high as $2B","url":"http:\/\/ct.moreover.com\/?a=29537917494&p=1pl&v=1&x=BEW07W0SwGEKF4d8Ht433w","license":"public","citation_ids":[5098679],"posted_on":"2017-02-10T12:18:48+00:00","summary":"Immunomedics (NASDAQ: IMMU ) jumps 28% premarket on increased volume in response to its announcement that it has entered into an exclusive global licensing agreement with Seattle Genetics (NASDAQ: SGEN ) for lead product product candidate IMMU-132 (sa\u2026","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}},{"title":"Immunomedics Pushes Forth On Sacituzumab Govitecan","url":"http:\/\/ct.moreover.com\/?a=30498643605&p=1pl&v=1&x=OHWIOF-CB_j5wvRTZFzcjg","license":"public","citation_ids":[19961702,16170275,4970429,5911199,19961703,1697692,2805347,19961704,19961705,3461741,19961708,5098679,19961709,18388266,19961710,19961711],"posted_on":"2017-05-08T18:36:39+00:00","summary":"Summary As part of Venbio takeover, Immunomedics exits licensing deal with Seattle Genetics and raises 125 million in cash with private placement of preferred stock.","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}}]}}